Global
Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Macular
Edema - Pipeline Review, H1 2018, provides an overview of the Macular
Edema (Ophthalmology) pipeline landscape.
Macular edema is swelling or
fluid retention in a specialized part of the retina called the macula. Symptoms
of macular edema include blurred or wavy central vision and/or colors appear
changed. There are many causes of macular edema. It is frequently associated
with diabetes, where damaged blood vessels in the retina begin to leak fluids,
including small amounts of blood, into the retina. Other causes include retinal
vein occlusion, side effects of certain medications and certain genetic
disorders, such as retinoschisis or retinitis pigmentosa.
Global
Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Macular
Edema - Pipeline Review, H1 2018, provides comprehensive information on the
therapeutics under development for Macular Edema (Ophthalmology), complete with
analysis by stage of development, drug target, mechanism of action (MoA), route
of administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.
The Macular
Edema (Ophthalmology) pipeline guide also reviews of key players involved in
therapeutic development for Macular Edema and features dormant and discontinued
projects. The guide covers therapeutics under Development by Companies
/Universities /Institutes, the molecules developed by Companies in Phase II,
Preclinical and Discovery stages are 2, 7 and 1 respectively.
Macular
Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging
players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage. The guide is built using data and information sourced
from Global Markets Direct's proprietary databases, company/university
websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic tracking
processes ensure that the most recent developments are captured on a real time
basis.
The pipeline
guide provides a snapshot of the global therapeutic landscape of Macular Edema
(Ophthalmology).
The pipeline guide reviews
pipeline therapeutics for Macular Edema (Ophthalmology) by companies and
universities/research institutes based on information derived from company and
industry-specific sources.
The pipeline guide covers
pipeline products based on several stages of development ranging from
pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive
drug profiles for the pipeline products which comprise, product description,
descriptive licensing and collaboration details, R&D brief, MoA & other
developmental activities.
The pipeline guide reviews key
companies involved in Macular Edema (Ophthalmology) therapeutics and enlists
all their major and minor projects.
The pipeline guide evaluates
Macular Edema (Ophthalmology) therapeutics based on mechanism of action (MoA),
drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates
all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest
news related to pipeline therapeutics for Macular Edema (Ophthalmology)
Procure strategically important
competitor information, analysis, and insights to formulate effective R&D
strategies.
Recognize
emerging players with potentially strong product portfolio and create effective
counter-strategies to gain competitive advantage.
Find and recognize significant
and varied types of therapeutics under development for Macular Edema
(Ophthalmology).
Classify potential new clients or
partners in the target demographic.
Develop tactical initiatives by
understanding the focus areas of leading companies.
Plan mergers and acquisitions
meritoriously by identifying key players and it's most promising pipeline
therapeutics.
Formulate corrective measures for
pipeline projects by understanding Macular Edema (Ophthalmology) pipeline depth
and focus of Indication therapeutics.
Develop and
design in-licensing and out-licensing strategies by identifying prospective
partners with the most attractive projects to enhance and expand business
potential and scope.
Adjust the
therapeutic portfolio by recognizing discontinued projects and understand from
the know-how what drove them from pipeline.
For more information on the research report,
refer to below link:
Related Reports:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
Ken Research
Ankur Gupta, Head Marketing & Communications
Sales@kenresearch.com
+91-9015378249
